Vaxcyte Dirección

Dirección controles de criterios 3/4

El CEO de Vaxcyte's es Grant Pickering , nombrado en Nov 2013, tiene una permanencia de 10.42 años. compensación anual total es $12.14M, compuesta por 5.3% salario y 94.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.61% de las acciones de la empresa, por valor de €37.51M. La antigüedad media del equipo directivo y de la junta directiva es de 3.9 años y 5 años, respectivamente.

Información clave

Grant Pickering

Chief Executive Officer (CEO)

US$12.1m

Compensación total

Porcentaje del salario del CEO	5.3%
Permanencia del CEO	10.9yrs
Participación del CEO	0.5%
Permanencia media de la dirección	4.4yrs
Promedio de permanencia en la Junta Directiva	5.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Grant Pickering en comparación con los beneficios de Vaxcyte?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$497m
Mar 31 2024	n/a	n/a	-US$437m
Dec 31 2023	US$12m	US$640k	-US$402m
Sep 30 2023	n/a	n/a	-US$300m
Jun 30 2023	n/a	n/a	-US$265m
Mar 31 2023	n/a	n/a	-US$245m
Dec 31 2022	US$14m	US$601k	-US$223m
Sep 30 2022	n/a	n/a	-US$174m
Jun 30 2022	n/a	n/a	-US$143m
Mar 31 2022	n/a	n/a	-US$118m
Dec 31 2021	US$5m	US$575k	-US$100m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$87m
Mar 31 2021	n/a	n/a	-US$83m
Dec 31 2020	US$3m	US$481k	-US$89m
Sep 30 2020	n/a	n/a	-US$83m
Jun 30 2020	n/a	n/a	-US$73m
Mar 31 2020	n/a	n/a	-US$64m
Dec 31 2019	US$596k	US$426k	-US$50m

Compensación vs. Mercado: La compensación total de Grant($USD12.14M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD3.36M).

Compensación vs. Ingresos: La compensación de Grant ha sido consistente con los resultados de la empresa en el último año.

CEO

Grant Pickering (56 yo)

10.9yrs

Permanencia

US$12,135,683

Compensación

Mr. Grant E. Pickering, M.B.A., is Co-Founder of Vaxcyte, Inc. since 2013 and has been its Chief Executive Officer and Director since November 2013 and served as its President since November 2013 until Dec...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Grant Pickering	Co-Founder	10.9yrs	US$12.14m	0.54% $ 68.0m
Andrew Guggenhime	President & CFO	4.4yrs	US$5.42m	0.044% $ 5.6m
James Wassil	Executive VP & COO	4.8yrs	US$5.40m	0.14% $ 17.0m
Mikhail Eydelman	Senior VP	2.5yrs	US$3.49m	0.0082% $ 1.0m
Ashish Khanna	Co-Founder	11.8yrs	sin datos	sin datos
Jeff Fairman	Co-Founder & VP of Research	no data	sin datos	sin datos
Elvia Cowan	Senior VP of Finance & Principal Accounting Officer	1.8yrs	sin datos	0.0032% $ 396.3k
Janet Graesser	Senior Vice President of Corporate Communications & Investor Relations	no data	sin datos	sin datos
Whitney Jones	Chief People Officer	less than a year	sin datos	sin datos
Paul Sauer	Senior Vice President of Process Development & Manufacturing	8.5yrs	US$2.35m	sin datos
Harp Dhaliwal	Senior Vice President of Commercial Manufacturing & Supply Chain	2.9yrs	US$1.84m	sin datos
Sam Iki	Senior Vice President of Project Management	no data	sin datos	sin datos

4.4yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 5VA se considera experimentado (3.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Grant Pickering	Co-Founder	10.9yrs	US$12.14m	0.54% $ 68.0m
Thomas Monath	Member of Scientific Advisory Board	no data	sin datos	sin datos
Annie Drapeau	Independent Director	3.1yrs	US$704.22k	0.0046% $ 570.7k
K. Hirth	Independent Director	8.1yrs	US$696.72k	0.010% $ 1.3m
Heath Lukatch	Independent Director	6.4yrs	US$691.72k	0.0046% $ 570.7k
Halley Gilbert	Independent Director	4.5yrs	US$704.22k	0.0046% $ 570.7k
Emmanuel Walter	Member of Scientific Advisory Board	no data	sin datos	sin datos
Carlos Paya	Independent Chairman of the Board	3yrs	US$724.22k	0.0046% $ 570.7k
Anthony Ford-Hutchinson	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jeffrey Almond	Member of Scientific Advisory Board	7.8yrs	sin datos	sin datos
Teri Loxam	Independent Director	3.1yrs	US$704.22k	0.0046% $ 570.7k
William Hausdorff	Member of Scientific Advisory Board	no data	sin datos	sin datos

5.5yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de 5VA se considera experimentada (5 años de antigüedad promedio).

Vaxcyte Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

High number of new directors

Recent updates

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion.

New major risk - Revenue and earnings growth

Vaxcyte, Inc. has filed a Follow-on Equity Offering.

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

New major risk - Shareholder dilution

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

High number of new directors

High number of new directors

Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Vaxcyte, Inc. Announces Executive Appointments

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults

High number of new directors

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad